Positive anti-myeloperoxidase antibody suggests that the patient may have primary vasculitis, primary necrotizing crescentic glomerulonephritis and allergic granulomatous vasculitis, etc., which need to be further improved to clarify the clinical diagnosis, and targeted drug treatment for the cause. Anti-myeloperoxidase antibody (MPO) is one kind of autoantibodies, which is commonly found in primary vasculitis, primary necrotizing crescentic glomerulonephritis, allergic granulomatous vasculitis, rheumatoid arthritis, systemic lupus erythematosus, and other diseases, and can be targeted for treatment after the clinical diagnosis is clarified, which is mainly based on drug therapy. The specific drug treatment program varies according to the specific type of patients, personal factors and other differences, such as primary vasculitis drug treatment includes glucocorticoids such as sodium acetate prednisone tablets, non-steroidal anti-inflammatory drugs such as celecoxib, cytotoxic drugs such as cyclophosphamide, etc., in addition to the above medications can be used in the treatment of systemic lupus erythematosus, such as belevulizumab. The above drugs should be used in accordance with medical advice. The test results should be interpreted by a professional physician, and patients with positive anti-myeloperoxidase antibodies are recommended to go to the Department of Rheumatology and Immunology or the Department of Nephrology of a regular hospital for detailed consultation.